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Prevalence and risk factors for 
Pulmonary Embolism (PE) and Deep 
Vein Thrombosis (DVT) during Acute 
Exacerbation of Chronic Obstructive 
Pulmonary Disease (AECOPD)
ABSTRACT
Introduction: COPD patients are at high risk for PE and DVT due to immobility, inflammation, comorbidities. 
Prevalence of PE during AECOPD is uncertain and often under-diagnosed. 
Material and methods: Single-center, prospective, an observational trial of 100 hospitalized patients with 
AECOPD, diagnosed according to GOLD criteria, 40–75 years, stratified according to airflow limitation 
(I–IV), divided into subgroups (PE-diagnosed/non-PE and with known/ undetermined exacerbation etiology). 
Investigations: clinical risk assessment, electrocardiogram (ECG), laboratory, spirometry, gas-analysis, 
D-dimer (DD), chest X-ray, thoracic ultrasonography (TUS), Doppler-ultrasonography of deep-veins of
lower-extremities (DULE). Patients with high DD and DVT or high DD and abnormal TUS underwent com-
puted-tomography pulmonary-angiography (CTPA). 
Results: PE was diagnosed in 26 (26.0%), DVT in 5 (5.0%) of hospitalized AECOPD patients. There was
a positive correlation between COPD-severity and PE. Frequencies of PE in GOLD-stages I, IV, were 0
(0.0%), 3 (11.5%), 8 (30.7%), 15 (57.7%) respectively. Patients with pleuritic chest-pain, TUS abnormality, 
phlebitis and high DD were more likely to develop PE. Localization was subsegmental in 9 (34.6%), in one 
of the main pulmonary arteries 7 (26.9%), lobar and interlobar arteries in 10 (38.5%). DD was significantly 
higher among patients with PE than those without (3.34 ± 1.1 μg/mL vs. 2.2 ± 0.8μg/mL, P < 0.0001). 
There was positive correlation between the presence of PE and elevated DD > 2.0 μg/mL (P = 0.02).
There was no statistically significant difference between patients with PE and without, according to age, 
gender and comorbidities (P > 0.05). Immobility and obesity were significantly higher among PE patients, 
P = 0.032 and P < 0.0001 respectively.
Conclusion: AECOPD associated with pleuritic chest pain, immobility, high DD, should be considered for 
PE. Chest-ultrasound, as a low-cost and safe procedure, can be a very helpful investigation. 
Key words: COPD, D-dimer, pulmonary embolism, deep vein thrombosis, chest ultrasonography, lung
computed tomography angiography
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Introduction
COPD is a major health burden worldwide. It is the 
fourth-leading cause of mortality, with more than 3 mil-
lion deaths annually and by 2020, COPD from fourth will 
become the third-world leading cause of death. COPD is 
a systemic disease with many comorbidities like cardio-
vascular disease, anemia, polycythemia, malnutrition, 
muscle disorder, osteoporosis, metabolic syndrome, 
diabetes, gastroesophageal reflux, anxiety, depression, 
hormonal imbalance, infections, lung cancer, thrombo-
sis [1]. Exacerbations of COPD are the episodic periods 
of the disease, characterized by deterioration of respi-
ratory function, requiring treatment with steroids and/or 
antibiotics. Most deaths caused by COPD appear to 
occur during exacerbations. AECOPD is a frequent 
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reason for a visit to the emergency department and 
hospitalization in medical wards. Respiratory infections 
are responsible for 50–70% of COPD exacerbations and 
environmental pollution causes another 10%. Nearly 
30% of all COPD exacerbations have unknown etiology 
[1, 2]. Many studies have shown that COPD is a moder-
ate and independent factor for PE. Patients with COPD 
are at high risk for PE because of systemic inflammation, 
limited mobility and co-existing comorbidities. PE can 
exacerbate respiratory symptoms such as dyspnea 
and chest pain [3]. The frequency of PE in patients 
with acute exacerbation of COPD remains uncertain 
[4]. Studies suggest that up to 30% of patients seen 
as emergencies with exacerbations of COPD may have 
DVT or PE [5, 6]. The prevalence of PE in post-mortem 
studies ranges from 28% to 51% [2]. Patients with COPD 
have almost double the risk of PE and other venous 
thromboembolic incidents than those with no COPD 
[7]. It was proved that DD is still the most useful test to 
exclude VTE with a negative predictive value of 98%. 
An elevated DD gives a more precise risk assessment 
for VTE when combined with a clinical scoring system 
like the revised Geneva score [8]. DD measurement is 
a simple and rather noninvasive test that rules out PE 
without the need for additional imaging procedures; 
unfortunately, there is still a debate about the efficacy 
of DD tests in diagnosing PE in patients suffering from 
acute exacerbation of COPD [9]. Irrespective of the 
presence of venous thromboembolism, DD levels are 
increased in patients with COPD exacerbation. With 
the advent of CTPA, it is now possible to visualise the 
clot by an imaging technique and reliably confirm the 
diagnosis of PE in COPD subjects. This technique car-
ries a high risk in some patients who are allergic to the 
contrast agent or have renal impairment with rtheisk of 
contrast nephropathy. Additionally, radiation exposure, 
high cost of CTPA, necessitates the search for a tool to 
reduce the need for unnecessary radiological investiga-
tion [10]. TUS in detecting PE with high sensitivity and 
diagnostic accuracy, is a non-invasive, widely available, 
cost-effective method which can be rapidly performed. 
A negative TUS study cannot rule out PE with certainty, 
but positive TUS findings with moderate/high suspicion 
for PE may prove a valuable tool in the diagnosis of 
PE, especially at emergency setting, for critically ill 
and immobile patients, facilitating immediate treatment 
decision [11]. TUS could suggest the diagnosis of PE 
by the presence of one or more typical pleural-based 
hypoechoic lesions that could be associated with pleu-
ral effusion or not [12]. Increased expression of VTE 
as PE in COPD patients may be problematic since the 
mortality of COPD patients with PE is particularly high, 
and COPD has been integrated with prognostic scores 
such as the Simplified Pulmonary Embolism Severity 
Index [13]. COPD has also been associated with inap-
propriate management in the case of suspected PE 
and the suggestion of PE may be challenging in COPD 
patients because of the similarities in symptoms [14]. 
Objective 
The objective of the present study was to evaluate 
the prevalence and risk factors for PE and DVT in hos-
pitalized patients with AECOPD.
Material and methods
Design and setting: Single-center, prospective, 
observational trial of 100 hospitalized patients with 
AECOPD (72 men and 28 women, aged 40–75 years, 
mean age 62.2 ± 6.8) who were hospitalized in the two-
year period 2018–2020 at Department of Pulmonology 
and Allergology at General Hospital “8mi Septemvri” 
in Skopje. AECOPD was diagnosed according to the 
recommendations of Global Initiative for Chronic Ob-
structive Lung Disease (GOLD). Our local ethics com-
mittee approved the study protocol. All study subjects 
were informed about the study and their written consent 
was obtained.
Investigations: Prospectively included patients with 
AECOPD were investigated by a diagnostic algorithm 
for PE. In first 48-hours of hospital admission was 
performed — collecting data for full medical histories; 
body weight with calculated body mass index (BMI), 
smoking history, clinical prediction rules for PE — re-
vised Geneva score and Wells criteria [15, 16], ECG, 
a blood sample for laboratory and arterial blood gas 
analysis, spirometry, serum DD, chest-X-ray, DULE, 
TUS, echocardiography. Patients with high DD and 
DVT or high DD and abnormal TUS underwent CTPA.
Inclusion criteria: COPD patients hospitalized 
because of AECOPD (diagnosed according to the rec-
ommendations of GOLD, as acute deterioration from 
a stable respiratory condition, which required hospi-
talization), age 40–75, both genders, current or former 
smokers, normal liver and kidney function (according 
to laboratory results — aspartate aminotransferase 
2–35 U/L, alanine aminotransferase 2–45 U/L, total 
bilirubin < 1.2 mg/dL, gamma-glutamyl transferase 
9–48 U/L, alkaline phosphatase 44–147 U/L  blood urea 
nitrogen < 8.3 mmol/L, serum creatinine 53–115 μmol/L 
and previous patient medical history), non-allergic to 
contrast, signed informed consent. 
Exclusion criteria: asthma, pneumothorax, lung 
fibrosis, active tuberculosis, sarcoidosis, malignan-
cies, hepatic, renal diseases, coagulation disorders, 
haematological diseases, congenital heart disease, 
myocardial infarction during the previous year (while 
antiplatelet therapy is necessary), regular therapy with 
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oral anticoagulant or antiplatelet medication, collagen 
vascular diseases, surgery in the previous 3 months, 
transfusion of blood or blood component in the previous 
3 months, not willing to participate.
AECOPD subjects were stratified based on medical 
history before exacerbation and spirometry (stages 
I–IV) according to GOLD criteria. Then, the patients 
were divided into 2 sub-groups: patients with AE-
COPD of known etiology and patients with AECOPD 
of undetermined etiology. AECOPD of known etiology 
tracheobronchitis, pneumonia discontinuation of COPD 
inhaler therapy or oxygen treatment, refused scheduled 
pulmonary rehabilitation, problems in nutritional status 
and congestive heart failure.
Patients were also classified according to the re-
sult of CTPA in PE-diagnosed subgroup and non-PE 
AECOPD patients.
In the first 48-hours after hospital admission pa-
tients were classified using Wells and revised Geneva 
criteria as low, moderate and high risk for pulmonary 
emboli. The score comprised 8 variables (points): age 
older than 65 years (1 point), previous deep venous 
thrombosis or pulmonary embolism (3 points), surgery 
or fracture within 1 month (2 points), active malignant 
condition (2 points), unilateral lower limb pain (3 points), 
hemoptysis (2 points), heart rate of 75 to 94 beats/min 
(3 points) or 95 beats/min or more (5 points), and pain 
on lower-limb deep venous palpation and unilateral ede-
ma (4 points). Low-probability category (0 to 3 points), 
intermediate-probability category (4 to 10 points), and 
high-probability category (> or = 11 points) [15, 16].
Laboratory analysis included routine biochemistry 
tests for liver, kidney function, glucose level, acute-
phase reactants (white blood cell count, erythrocyte 
sedimentation rate, C-reactive protein), troponin 
and DD.
DD was measured with DD-assay system (Boeh-
ringer, Germany), which is a particle-enhanced immu-
noturbidimetric assay, level below 0.5 mcg/mL was 
considered to be within the normal range.
Arterial blood gas analyses were performed with SIE-
MENS RAPIDPOINT 405 System (Siemens Healthineers, 
Australia). Interpretation of the results: hypercapnia 
PaCO2 > 45 mmHg, hypocapnia PaCO2 < 35 mmHg, 
acidosis pH < 7.35, alkalosis pH > 7.45, hypoxemia 
PaO2 < 80 mmHg (mild 60–80 mmHg, moderate 
40–59 mmHg,  severe < 40 mmHg).
Pre-bronchodilator (baseline) spirometry measured 
forced vital capacity (FVC), forced expiratory volume in 
one second (FEV1), FEV1/FVC ratio, maximal expiratory 
flow at 75%, 50%, 25%, and 25–75% of FVC by elec-
tronic spirometer Spirobank G USB Spirometer (Medical 
International Research, Roma, Italy). The results of 
measurements were expressed as percentages of the 
predicted values following the actual recommendations 
of the European Respiratory Society (ERS) and the 
American Thoracic Society (ATS). Post-bronchodilator 
spirometry was performed 20 minutes after administra-
tion of 400 mcg salbutamol and fixed airflow narrowing 
was considered if post-bronchodilator FEV1/FVC value 
remained less than 0.70. 
DULE was performed using General Electric Vivid 
7 ultrasound unit, linear transducer (6–10 MH), starting 
from a common femoral vein and including the calf vein. 
Lack of compressibility was considered to indicate deep 
venous thrombosis.
TUS was performed by a chest physician with Gen-
eral Electric Vivid 7 ultrasound device using a convex 
probe (3.5 MHz). If the patient had chest pain, the 
examination started from the painful area and then 
all intercostal areas were obtained in six vertical lines 
(paravertebral, midscapular, posterior axillary, midax-
illary, anterior, axillary, and midclavicular). Findings 
were described like pleural-based hypoechoic lesions 
(wedge-shaped, round or triangular) that could be 
associated with pleural effusion or not, nonspecific 
subpleural hypoechogenic lesion and normal finding. 
Presence of pleural effusion without subpleural changes 
or normal ultrasonography finding were accepted as 
negative TUS for PE.
CTPA was performed to show emboli in the lung 
with a 16-section multidetector CT scanner (GE Light 
Speed 16; GE Healthcare, Milwaukee, Wisconsin, USA) 
within 24 h of admission). Patients with high DD and 
DVT or high DD and abnormal TUS underwent CTPA. 
CT-scans for thorax were obtained in the craniocaudal 
direction during a single inspiratory breath hold from 
the apex to the diaphragm after injection of 2 mL/kg 
(maximum 150 mL) of nonionic contrast Iopromide 
(Ultravist-300, Bayer Pharma), through an arm vein. 
Reconstruction interval was 2 mm. PE was diagnosed if 
contrast material outlined an intraluminal defect present 
in at least two consecutive images, or if the vessel was 
occluded by low attenuation material. The localization 
of the thrombi was noted. 
Cardiac function was evaluated with ECG and 
resting 2D Doppler Echocardiography  (performed by 
a cardiologist using General Electric Vivid 7, according 
to the recommendations of the American Heart Associ-
ation), to detect direct and indirect signs of pulmonary 
emboli. Echocardiography finding of right ventricular 
dilation (when Right Ventricular End Diastolic dimension 
— RVEDd exceeded the normal range of 0.9–2.6 cm), 
leftward moving of interventriculer septum, pulmo-
nary hypertension (defined as a systolic Pulmonary 
Artery Pressure — sPAP value equal to or higher than 
30 mmHg), hypokinesis of the right ventricle. Sinus 
tachycardia, atrial fibrillation, T wave abnormalities, 
pattern, bundle branch block, right axis deviation, 
S1Q3T3 on ECG.
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Statistical analysis
Statistical analysis was done using the Statistical 
Package for the Social Sciences (SPSS) version 17.0 for 
Windows (SPSS. Inc., Chicago, IL, USA). Continuous 
variables were expressed as mean values with standard 
deviation (SD). Most of the results were with numerical 
values and Pearson Correlation test was performed for 
comparison. The nominal variables were presented as 
numbers and percentages. The level of P-value less 
than 0.05 was considered as statistically significant.
Results 
A total of 100 hospitalized patients with AECOPD, 
according to the inclusion and exclusion criteria were 
enrolled as the study group. The investigated group 
included 62 men, 38 women, age 40–75. PE was diag-
nosed in 26 (26.0%) of investigated group and DVT in 
5 (5.0%). According to the presence of pulmonary em-
bolism on CTPA, patients were divided in two groups: 
with PE (n = 26) and non-PE patients (n = 74). There 
was no statistically significant difference between pa-
tients with PE and without, according to age, gender, 
spirometry and comorbidities (P > 0.05). Immobility 
and obesity were significantly higher among patients 
with PE, P = 0.032 and P < 0.0001 respectively. Char-
acteristics of the study subjects are presented in Table 
1. According to the revised Geneva score, 55 (55.0%) 
of all 100 patients had a low probability of PE and in 
10 (18.2%) of these 55 patients, PE was confirmed. 
Forty-two patients (42.0%) of the investigated group, 
had an intermediate probability of PE and 25 (59.5%) 
of them, had confirmed PE. Three of 100 investigated 
patients had a high probability of PE and in all of them 
(100.0%), PE was diagnosed. Previous DVT or PE were 
significantly more prevalent in PE group than non-PE 
group (23.1% vs. 10.8%, P < 0.05) (Tab. 2). 
Frequency of PE proportionally increased in AE-
COPD patients as FEV1 declined, presented in Table 3. 
According to AECOPD etiology, patients were divid-
ed into 2 sub-groups: patients with AECOPD of known 
etiology and patients with AECOPD of undetermined 
etiology presented in Table 4.
Patients with pleuritic chest-pain, abnormal TUS, 
DVT and high DD were more likely to develop PE. DD 
was significantly higher among patients with PE than 
those without (3.34 ± 1.1 μg/mL vs. 2.2 ± 0.8 μg/mL, 
P < 0.0001). There was correlation between the pres-
ence of PE and elevated DD > 2.0 μg/mL (P = 0.02). The 
presence of DVT in investigated group of 100 patients 
was 5 (5.0%) and all of them were diagnosed with PE 
(PE group, n = 26). DVT was significantly higher in 
PE group vs. non-PE group (P < 0.005). Electrocar-
diographic abnormalities such as atrial fibrillation or 
right bundle branch block appeared more often, but 
the S1Q3T3 pattern appeared less often. They also 
Table 1. Characteristics of the study subjects
Characteristic Group 1 
(PE group)
(n = 26)
Group 2 
(non-PE group)
(n = 74)
P value
Gender
Male
Female
17 (65.4%)
9 (34.6%)
45 (60.8%)
29 (39.2%)
P = 0.6792
Mean age 
Male
Female
62.9 ± 6.5
63.9 ± 6.1
61.3 ± 8.1
64.3 ± 7.4
P = 0.3657
P = 0.8051
Smoking status
Current smokers
Ex-smokers
Pack-year smoked
16 (61.5%)
10 (38.5%)
56.3 ± 20.8
50 (67.6%)
24 (32.4%)
54.7 ± 19.5
P = 0.5741
Mean BMI value 30.8 ± 4.9 25.9 ± 3.1 P < 0.0001
Mean baseline spirometry 
FVC (% pred)
FEV1 ((% pred)
FEV1/FVC ratio
66.8 ± 10.1 
45.5 ± 15.9
0.58 ± 0.05
67.2 ± 9.7 
47.4 ± 15.4
0.60 ± 0.05
P = 0.8583
P = 0.5927
P = 0.0825
Blood gas analysis
PaO2 (kPa)
PaCO2 (kPa)
O2 saturation (%)
8.1 ± 1.1
5.5 ± 1.8
84.6 ± 5.3
8.3 ± 1.6
5.1 ± 1.7
86.6 ± 7.3
P = 0.5570
P = 0.2975
P = 0.2030
BMI — body mass index; FVC — forced vital capacity; FEV1 — forced expiratory volume in one second; % pred — percentage of the predicted 
value; PaO2 — Partial Pressure of Oxygen; PaCO2 — Partial Pressure of Carbon dioxide; O2 — Oxygen; kPa — Kilopascal
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Table 2. Study sample characteristics according to The Revised Geneva Score [16]
Variable Group 1 (PE group)
(n = 26)
Group 2 (non-PE group)
(n = 74) P value
Risk factors
Age > 65 years 14 (53.8%) 35 (47.3%) P = 0.5704
Previous DVT or PE 5 (19.2%) 4 (5.4%) P = 0.0352
Recent surgery Not applicable
(exclusion criteria)
Not applicable
(exclusion criteria)
/
Active malignant condition Not applicable
(exclusion criteria)
Not applicable
(exclusion criteria) /
Symptoms
Unilateral lower-limb pain 5 (19.2%) 3 (2.7%) P = 0.0047
Hemoptysis 7 (26.9%) 0 (0.0%)     P < 0.0001
Clinical signs
Heart rate: 75–94 beats/min
≥ 95 beats/min
23 (88.5%) 45 (60.8%) P = 0.0096
Pain on lower-limb venous 
palpation, unilateral edema
4 (15.4%) 2 (2.6%)
P = 0.0180
Clinical probability
Low risk (0 to 3 points, n = 55) 10 (18.2%) 45 (81.8%) P < 0.0001
Intermediate risk (4 to 10 points, 
n = 42)
25 (59.5%) 17 (40.5%) P = 0.0958
High risk (> or = 10 points, n = 3) 3 (100.0%) 0 (0.0%) P < 0.0001
DVT — deep vein thrombosis; PE — pulmonary embolism
Table 3. Distribution AECOPD patients with diagnosed 
Pulmonary Embolism (PE) based on the degree of 
airflow limitation
COPD severity Patients with 
diagnosed PE (n = 26)
GOLD 1 (FEV1 ≥ 80% pred.) 0 (0.0%)
GOLD 2 (FEV1 = 50–79% pred.) 3 (11.5%)
GOLD 3 (FEV1 = 30–49% pred.) 8 (30.7%)
GOLD 4 (FEV1 < 30% pred.) 15 (57.7%)
COPD — chronic obstructive pulmonary disease; PE — pulmonary 
embolism; GOLD — Global Initiative for Chronic Obstructive Lung 
Disease; FEV1 — forced expiratory volume in one second; % pred — 
percentage of the predicted value
Table 4. Etiology of acute COPD exacerbation
AECOPD etiology of hospitalized patients (n = 100)
Known etiology 68 (68.0%)
Tracheobronchitis 25 (25.0%)
Pneumonia 20 (20.0%)
Discontinuation of COPD inhaler therapy 15 (15.0%)
Congestive heart failure 8 (8.0%)
Undetermined etiology 32 (32.0%)
COPD — chronic obstructive pulmonary disease; AECOPD — Acute 
Exacerbation of Chronic Obstructive Pulmonary Disease
had a higher frequency of hypoxemia and hypercap-
nia. Hospital stay duration was longer in PE group 
(14 ± 4 days in PE group vs. 9 ± 2 days in non-PE 
group, P < 0.0001). The presence of symptoms of 
respiratory infection was less common in PE group, in 
13 (50.0%) vs. 65 (87.8%) of non-PE group (P = 0.0001, 
95% CI 17.5603 to 56.6053%). TUS was true positive in 
24 (24.0%) patients, true negative in 54 (54.0%), false 
positive in 20 (20.0%) and false-negative in 2 (2.0%). 
The results of the localization of pulmonary emboli on 
CTPA and TUS findings are presented in Table 5.
Discussion
Clinical diagnosis of acute PE is difficult in patients 
with COPD. Pulmonary embolism resembles COPD 
exacerbation so closely that these two entities are 
often impossible to distinguish clinically. The reported 
incidence of PE in studies done postmortem of patients 
with COPD ranges from 28% to 51% [17]. But the prev-
alence of PE in studies performed in living patients with 
COPD is lower than when autopsy is done, ranging 
from 3–25%. Since PE can lead to cough and dys-
pnea, similarly to infectious events, there is a difficulty 
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Table 5. Results of Computed Tomography with Pulmonary Angiography (CTPA) and Thoracic Ultrasonography 
(TUS) findings
Analysis of CTPA and TUS in PE group (n = 26)
                      Localization of PE on CTPA TUS findings in PE group
Main pulmonary artery   7 (26.9%) Pleural-based hypoechoic 
lesions with/or without 
pleural effusion
Total 15 (57.7%)
with pleural effusion 8(30.8%)
without pleural effusion 7 (26.9%)
Lobar and interlobar arteries 10 (38.5%) Nonspecific subpleural 
hypoechogenic lesion
9 (34.6%)
Subsegmental arteries 9 (34.6%) Normal finding 2 (7.7%)
CTPA — computed tomography with pulmonary angiography; TUS — thoracic ultrasonography; PE — pulmonary embolism
in excluding lower respiratory tract infection. Nearly 
30% of all exacerbations of COPD do not have a clear 
etiology [18]. The most common causes of exacer-
bation are infection of the tracheobronchial tree and 
air pollution, but in up to 30% of exacerbations, the 
specific cause cannot be identified. Although PE can 
exacerbate respiratory symptoms such as dyspnea 
and chest pain, and COPD patients are at high risk for 
PE due to a variety of factors including limited mobility, 
inflammation, and comorbidities, the prevalence of 
PE during exacerbations is uncertain. Generally, the 
prevalence of VTE including PE has been found to be 
markedly lower in Asians than in whites and African 
Americans [18, 19]. According to RIETE registry, 
COPD patients presenting with PE have an increased 
risk for PE recurrences and fatal PE compared with 
those presenting with DVT alone [20]. 
Our study aimed to assess the prevalence and risk 
factors for PE and DVT in hospitalized patients with 
AECOPD. We performed a single-center, observational, 
prospective study, including 100 patients with AECOPD 
(62 male, 38 female), aged 40 to 75 years, diagnosed 
according to the actual GOLD criteria, stratified accord-
ing to airflow limitation (I–IV), divided into subgroups 
(PE-diagnosed and non-PE, with known and unde-
termined exacerbation etiology). PE was diagnosed 
in 26 (26.0%) and DVT in 5 (5.0%) of the investigated 
group. In August 2019, Hassen et al. presented the re-
sults of prospective cohort study about the incidence of 
PE in severe AECOPD requiring mechanical ventilation. 
The incidence of PE was 13.7% and was associated with 
high mortality [3]. The same result of PE prevalence 
13.7%, reported Gunen et al. in 2010 [10]. Choi et al. 
[18] in 2013, published a study of the prevalenceof PE 
and DVT in Koreans with COPD exacerbation, and the 
result was 5.0%, confirming the lower prevalence of PE 
in the Asian population. These results are lower than 
our study, but Akpinar et al. [2] in 2014 published the 
results of a study performed in Ankara, Turkey with the 
prevalence of PE in AECOPD 29.1%. Tillie-Leblond et 
al. [17] also found the prevalence of PE to be 25.0% 
in COPD patients with severe AECOPD of unknown 
etiology. Pang et al. [21] in 2018 reported DVT in AE-
COPD in 5.6% of the patients, similar to our study 5.0%. 
In our study, patients with pleuritic chest pain, abnor-
mal chest-ultrasound, phlebitis on DULE and high DD 
were more likely to develop PE. DD was significantly 
higher among patients with PE than those without 
(3.34 ± 1.1 μg/mL vs. 2.2 ± 0.8 μg/mL, P < 0.0001). 
This finding is in agreement with Akpinar et al. [2] who 
found significantly higher DD levels in COPD patients 
than control subjects, and the hospital stay duration was 
longer in the patients with PE than in those without, like 
in our study. Choi et al. [18] in contrast presented no 
difference in hospital stay duration. Our results about 
localization of pulmonary emboli on CTPA, showed 
higher prevalence of emboli in main, lobar and interlobar 
arteries than peripheral (subsegmental) localization. 
This finding is similar to the results of Choi et al. [18] 
but in contrast with Akpinar et al. [2], where peripheral 
localization was more frequent.
The results of the gas analysis showed no significant 
difference between the group with PE and without, sim-
ilar to Gunen et al. [11]. Akpinar et al. [2] presented re-
spiratory alkalosis and hypocapnia were more common 
in patients with COPD exacerbation accompanying PE.
TUS was applied to all patients in this study and 
high probability for PE was the presence of at least one 
typical subpleural hypoechoic lesion with or without 
pleural effusion. TUS was true positive in 24 (24.0%) 
and false-negative in 2 (2.0%) which is similar to the 
results published by Baz et al. [22] in 2019 that TUS 
with its high specificity and diagnostic accuracy should 
be widely performed in AECOPD patients.
Conclusions
This trial shows that PE is not uncommon in our pop-
ulation and one of four COPD patients who require hos-
pitalization for AECOPD may have PE, especially cases 
with unexplained respiratory exacerbation, immobility, 
high DD. Clinical manifestations of PE like dyspnoea, 
pleuritic chest pain are nonspecific, and easily could 
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be underestimated in subjects with COPD, which leads 
to disease worsening, delay of anticoagulant therapy 
and higher mortality rate. Thoracic ultrasonography 
as a low-cost and safe procedure can be a very help-
ful investigation.
The findings of the present study are subjects of 
some limitations. First, only one  center is included and 
relatively small size of the study subjects could have 
certain implications on evaluated data and its interpre-
tation. Second, the unequal distribution of COPD pa-
tients by degree of airflow limitation could have certain 
influence on data obtained and its interpretation. On the 
other side, the strength of the study is the diagnostic 
assessment of venous thromboembolism (PE and DVT) 
in hospitalized AECOPD patients, using clinical risk 
assessment, TUS, CTPA and DULE. 
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